---
id: 113
title: Acinetobacter baumannii and MDR Management
category: organisms
subcategory: gram_negative_rods
tags: [Acinetobacter, MDR, CRAB, carbapenem-resistant, polymyxin, sulbactam]
difficulty: medium
---

## Question

How is MDR *Acinetobacter baumannii* treated? Use the **"Sulbactam-Based Therapy or Polymyxins + Combination"** framework.

## Answer

### ***Acinetobacter baumannii* Overview:**

**Clinical Significance:**
- **Nosocomial pathogen** (ICU, ventilators, traumatic injuries)
- **Often MDR** (carbapenem-resistant *A. baumannii*, CRAB)
- **Biofilm formation** on medical devices
- **Dessication-resistant** (survives on dry surfaces)

**Common Infections:**
- Ventilator-associated pneumonia (VAP)
- Catheter-related bloodstream infections
- Wound infections (military, trauma)
- Meningitis (post-neurosurgery)

### **Treatment by Susceptibility:**

| Susceptibility | Treatment | Duration |
|----------------|-----------|----------|
| **Susceptible** (rare) | **Ampicillin-sulbactam** 3g IV q6h OR **cefepime**, **meropenem** | 7-14 days |
| **CRAB (Carbapenem-Resistant)** | **Sulbactam-based:** **Ampicillin-sulbactam 9g q8h** (high-dose) + **tigecycline** or **polymyxin** | 14-21 days |
| **Pan-Resistant** | **Polymyxin B** (or colistin) + **tigecycline** + **high-dose sulbactam** OR **cefiderocol** | 14-21 days |

### **Preferred Regimens for CRAB:**

**Option 1: Sulbactam-Based**
- **Ampicillin-sulbactam 9g IV q8h** (high-dose, for sulbactam 3g q8h)
- ± **Polymyxin B** 15,000-25,000 units/kg/day (divided q12h) OR **colistin**
- ± **Tigecycline** 100mg IV × 1 → 50mg IV q12h

**Option 2: Polymyxin-Based**
- **Polymyxin B** + **tigecycline** + **high-dose meropenem** (if MIC ≤16)
- **Triple combination** preferred for bacteremia/severe infections

**Option 3: New Agents**
- **Cefiderocol** 2g IV q8h (active against CRAB, MBL-producing)
- Concerns about mortality signal in trials (use with caution)

### **Meningitis (Post-Neurosurgery):**
- **Systemic:** High-dose sulbactam OR polymyxin + tigecycline
- **± Intrathecal/intraventricular polymyxin B** 5mg daily (severe, refractory)

## Key Points

### **Why Sulbactam:**
- **Intrinsic activity** against *Acinetobacter* (inhibits PBP)
- **Ampicillin-sulbactam:** Ampicillin is inactive, sulbactam is the active component
- **High-dose sulbactam** (3g q8h) required for CRAB

### **Polymyxins (Colistin, Polymyxin B):**
- **Last-resort** agents
- **Nephrotoxicity** (dose-dependent, monitor renal function)
- **Dosing:** Weight-based, loading dose recommended
- **Polymyxin B preferred** over colistin (less nephrotoxic)

### **Tigecycline:**
- **Bacteriostatic**
- **Low serum levels** (poor for bacteremia)
- **Best for:** Pneumonia, intra-abdominal infections (high tissue penetration)
- **Black box warning:** Increased mortality vs comparators (FDA warning)

### **Combination Therapy Rationale:**
- **Synergy** (polymyxin + carbapenem, polymyxin + tigecycline)
- **Prevent resistance emergence**
- **Improved outcomes** in severe infections (bacteremia, VAP)

### **Clinical Pearls:**
- **CRAB:** High-dose sulbactam (ampicillin-sulbactam 9g q8h) ± polymyxin/tigecycline
- **Combination therapy preferred** for severe infections
- **Polymyxin B** preferred over colistin (less nephrotoxic)
- **Tigecycline:** Poor for bacteremia (low serum levels)
- **Cefiderocol:** New option for CRAB, but mortality concerns
- **Infection control critical:** Contact precautions, environmental cleaning

## Sources

- [IDSA: MDR Gram-Negative Guidelines 2024]
- [ESCMID: *Acinetobacter* Management 2023]

## Media

N/A
